Compound Detail
CHEMBL440294
PIPAMPERONE 🧪 Phase III
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
🧪 Phase III
Basic Information
| ChEMBL ID | CHEMBL440294 |
| Name | PIPAMPERONE |
| Phase | Phase III |
| Structure Type | MOL |
| InChI Key | AXKPFOAXAHJUAG-UHFFFAOYSA-N |
1
Targets
4
Activities
2
Assay Types
0
PK Parameters
20
Publications
8
Known Names
7
Indications
Molecular Properties
375.5
MW (Da)
2.59
ALogP
4
HBA
1
HBD
66.6
PSA (Ų)
0.74
QED
0
Ro5 Violations
7
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| Chirality | Achiral |
Indications
Anxiety Dementia Depressive Disorder Depressive Disorder, Major Psychotic Disorders Psychotic Disorders Schizophrenia
ATC Classification
N05AD05
pipamperone
Level 1: NERVOUS SYSTEM
Level 2: PSYCHOLEPTICS
Activity Summary
IC50 2 meas. best 8.27
Ki 2 meas. best 8.86
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Rattus norvegicus CHEMBL376 | Ki | 8.86 | 8.44 | 1.4 | 2 |
| Rattus norvegicus CHEMBL376 | IC50 | 8.27 | 7.995 | 5.4 | 2 |
Activity Data Samples
Top measurements by pChEMBL value
| Target | Type | Rel. | Value | Units | pChEMBL | Assay | PubMed |
|---|---|---|---|---|---|---|---|
| Rattus norvegicus | Ki | = | 1.39 | nM | 8.86 | Compound was evaluated for its activity at membrane-bound receptor (M+L+P fracti... | 3746815 |
| Rattus norvegicus | IC50 | = | 5.37 | nM | 8.27 | Compound was evaluated for its activity at membrane-bound receptor (M+L+P fracti... | 3746815 |
| Rattus norvegicus | Ki | = | 9.53 | nM | 8.02 | Compound was evaluated for its activity at solubilized receptor (CHAPS/salt-solu... | 3746815 |
| Rattus norvegicus | IC50 | = | 19.05 | nM | 7.72 | Compound was evaluated for its activity at solubilized receptor (CHAPS/salt-solu... | 3746815 |
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 3746815 | 10.1021/jm00159a017 | Rattus norvegicus | 4 |
| 37468498 | 10.1038/s41467-023-40064-9 | Thromboxane A2 receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Prostaglandin G/H synthase 1 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Alpha-1A adrenergic receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Muscarinic acetylcholine receptor M1 | 2 |
| - | 10.6019/CHEMBL4651402 | SARS-CoV-2 | 2 |
| 18027916 | 10.1021/jm070524a | No relevant target | 2 |
| 36940609 | 10.1016/j.bmc.2023.117239 | Chikungunya virus | 1 |
| 37468498 | 10.1038/s41467-023-40064-9 | D(1A) dopamine receptor | 1 |
| 37468498 | 10.1038/s41467-023-40064-9 | Voltage-gated inwardly rectifying potassium channel KCNH2 | 1 |
| - | 10.1101/2020.04.21.054387 | SARS-CoV-2 | 1 |
| 37468498 | 10.1038/s41467-023-40064-9 | Estrogen receptor | 1 |
| 37468498 | 10.1038/s41467-023-40064-9 | Acetylcholinesterase | 1 |
| 37468498 | 10.1038/s41467-023-40064-9 | Sodium-dependent noradrenaline transporter | 1 |
| 37468498 | 10.1038/s41467-023-40064-9 | Sodium-dependent serotonin transporter | 1 |
| 37468498 | 10.1038/s41467-023-40064-9 | Alpha-2A adrenergic receptor | 1 |
| 37468498 | 10.1038/s41467-023-40064-9 | Mu-type opioid receptor | 1 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 1A | 1 |
| 37468498 | 10.1038/s41467-023-40064-9 | Vascular endothelial growth factor receptor 2 | 1 |
| 18027916 | 10.1021/jm070524a | Unchecked | 1 |
Data from ChEMBL 36 via Core Engine